{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=24",
    "query": {
      "intervention": "Phase duration",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 3753,
    "total_pages": 376,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+duration&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T22:39:06.490Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07490301",
      "title": "A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "PDAC"
      ],
      "interventions": [
        {
          "name": "Telisotuzumab adizutecan",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Folinic acid/ Leucovorina",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2026-04-30",
      "completion_date": "2031-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 9,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Zion, Illinois + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Zion",
          "state": "Illinois"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07490301"
    },
    {
      "nct_id": "NCT01579929",
      "title": "Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "LDE225, Etoposide and Cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2012-04",
      "completion_date": "2017-08-11",
      "has_results": false,
      "last_update_posted_date": "2017-08-17",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rockville Centre",
          "state": "New York"
        },
        {
          "city": "Sleepy Hollow",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01579929"
    },
    {
      "nct_id": "NCT03652545",
      "title": "Multi-antigen T Cell Infusion Against Neuro-oncologic Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "TAA-T",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catherine Bollard",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "6 Months to 80 Years"
      },
      "enrollment_count": 33,
      "start_date": "2018-12-12",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-14",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03652545"
    },
    {
      "nct_id": "NCT04401995",
      "title": "Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Vidutolimod (CMP-001)",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "[18F]F-AraG PET/CT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Diwakar Davar",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2020-09-02",
      "completion_date": "2024-08-16",
      "has_results": true,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04401995"
    },
    {
      "nct_id": "NCT04686279",
      "title": "Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV/AIDS",
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Tenofovir Douche",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "24 Years",
        "sex": "MALE",
        "summary": "15 Years to 24 Years · Male only"
      },
      "enrollment_count": 8,
      "start_date": "2021-04-01",
      "completion_date": "2022-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-10-30",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04686279"
    },
    {
      "nct_id": "NCT03680105",
      "title": "A Safety and Tolerability Study of RJX Drug Product in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Critical Limb Ischemia"
      ],
      "interventions": [
        {
          "name": "RJX",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 76,
      "start_date": "2018-08-24",
      "completion_date": "2019-01-15",
      "has_results": true,
      "last_update_posted_date": "2020-04-27",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03680105"
    },
    {
      "nct_id": "NCT05660746",
      "title": "Precise Infliximab Exposure and Pharmacodynamic Control",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Crohn Disease"
      ],
      "interventions": [
        {
          "name": "RoadMAB",
          "type": "DEVICE"
        },
        {
          "name": "Infliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "6 Years to 22 Years"
      },
      "enrollment_count": 180,
      "start_date": "2023-07-01",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05660746"
    },
    {
      "nct_id": "NCT00524303",
      "title": "Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neoplasms, Breast"
      ],
      "interventions": [
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "FEC75",
          "type": "DRUG"
        },
        {
          "name": "Lapatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2007-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-11-11",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 23,
      "location_summary": "Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00524303"
    },
    {
      "nct_id": "NCT07097142",
      "title": "Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Stage II Bladder Cancer AJCC v8",
        "Stage IIIA Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Mitomycin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Ultrahypofractionated Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 486,
      "start_date": "2025-10-07",
      "completion_date": "2035-05-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 258,
      "location_summary": "Fairbanks, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 196 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07097142"
    },
    {
      "nct_id": "NCT00977548",
      "title": "Erlotinib Study for Myelodysplastic Syndrome (MDS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2009-09",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2013-09-16",
      "last_synced_at": "2026-10-28T22:39:06.490Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00977548"
    }
  ]
}